University of Basel investigating active substances against the coronavirus
The University of Basel is using computer-aided methods in its efforts to find an active substance to fight the coronavirus. A total of just under 700 million substances have been tested on a virtual basis. This has allowed interesting substances to be identified already.
Research (Img: FreeImages.com)
The search for an active substance effective against the coronavirus is being advanced by a Computational Pharmacy research group at the Department of Pharmaceutical Sciences of the University of Basel, as detailed in a press release. The research group is being headed up by Markus Lill and has conducted virtual screening, as part of which more than 680 million substances have already been tested on a virtual basis.
The tests are focused on an important enzyme of the coronavirus, namely the central protease. If the virus’s critical enzyme can be inhibited, this can prevent it from further multiplying. A number of “interesting substances” have already been identified. “Even if the complete development of a drug to fight this particular coronavirus is likely to exceed the duration of the current epidemic, it is important to develop drugs for future coronaviruses”, Lill explains in the press release.
The Basel-based research group’s recent work should serve as a foundation. This is also illustrated by the fact that the research group has taken the decision to immediately make “the test results publicly available in the form of an open-source preprint”. The aim of the Basel researchers is therefore to allow other research groups to make use of their proposals and test potential drug candidates themselves. This approach is rooted in the current emergency situation, given that it is otherwise customary for interesting substances to be first experimentally tested together with other research groups before the results are patented and published, the press release states.
Share this article
You might also be interested in
A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.Read More
The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..Read More
Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.Read More
Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.Read More
The investment and innovation promotion agency Basel Area Business & Innovation, previously known as BaselArea.swiss, can look back on a successful year in 2019. In this regard, positive developments in the healthtech sector and in Switzerland Innovation Park Basel Area stand out.Read More
The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.Read More
The Basel-based Botnar Research Center for Child Health is providing capital in the amount of 15 million Swiss francs to its four partner institutions. In this way, the University of Basel should be in a position to advance research into dealing with the coronavirus outbreak.Read More